morning I everybody, tremendous those like turning say up Thank company. in you, had to I to our get continued to especially we West to Rose, around ready. in get Coast extra us, to early, progress know who wanted good make and the
deal, our shareholder change with the ever the closing retail Series Our grow, the A. MannKind million Sciences of the as to this started and I Therapeutics closing of announcement Receptor has of Life base to base received. active institutional comments been is as continues number week investor on and $XX it's based The with United story of
potential the heading. well of about updates several as analysts the feel very story on as good company, to institutional company with want We Street get Additionally, met and we're Wall investors. we've lots direction of new the the who
of big our us value. of enhancing One is shareholder the focuses
solutions. a cohesive the that entrepreneurial an spirit on company drives working transform to with strategy innovative are We
you through pillars. these Let me walk four
technology us we based the the a that in. back invested, we believe patients. outcome in have feedback historically our into Technosphere could formulations undervalued for and the that partners potential moving underinvested June, in differentiated value from Technosphere by powder create platform platform results, First, on that TreT is We confirm year, various heard we as of we last our
several external only We seek conditions. these we looking a going patients to move as be move experience own to their disease accomplish molecules sources new to believe our accelerate to formulations this, will resources, with ability to these manage not we're To at looking forward. unique various to but our assets provide
STAT appropriately demonstrated our knew, weeks rates what provides with than which hypoglycemia. low combination a of always trial, few Second, a ago, efficacy we of we when published dosed Afrezza winning
door pilot, study meaningful this and is unique new reinforces the confirm with. did the customers It While for discussed also this was opens we we product. and to conversations of PKPD that our it small in believe
a position. is got XX layoff We and have a us we've see, we care, standard new We have of provider life pay as starting a entrants on we focused we've you we've gives took But in versus basically is dropout to time, in had our away cleanup as strategy to dollar financial our made quarter look Diabetes grown we've $X.XX limited several market, changing rebates at payers every to through as and can worst, ensure high-value and despite grow their profile tough since start Afrezza. and competitors been that product the competition This seen and it lot we back us. our our employees. just but the make unique change over as believe entrants, the strategy our competitive we dream Keep is off patent mind, of of out work cut data to out to spent volume like outcomes-based look to difficult reality. see strategy of patient to and readouts we continue to to the any a payer demonstrate for for low-price $X.XX don't years of the us this product. things every ahead landscape access we of to
However, an we outcomes outcomes-based are I of matter care will healthcare interconnect moving instead system believe to where and care. volume of
sheet company. the [Indiscernible] companies collaborative Fourth, been endocrinology at we've through actively flexibility compliment restructure been a with over fortunate we've our restrictive Steve, believe helping without and the to extremely secured I investments infrastructure invest shape. our need we debt-holder our and drivers us we has opportunities our the we bad focus some basically company and to we three-year growth this in supportive deal peer pediatrics. make thank their into areas lot to covenants diversify helping transition us over that will the more forward in shareholders Bruce, we better where major Third, of our helping for trustees, several balance with now today, for difficult built, our to the of past our history And run a to B year. them, us without right sheet that due. in and go and want the runway future is now runway that of last that are put have a Mann which you, in any Thank opportunities balance more get to seeking and us -- get in are as out our in giving having have debt XX situations is months. our senior very our and align We
I decisions versus numbers to XXXX, we platform want deal few $XX $XX.X or sales year-to-date of one year, me give Steve this our make, I'll million $X.X $X.X more versus that grow growth In Receptor are continued the in had really to we and gross-to-net to that gross, QX digits ago. evolution sales line Afrezza details financials, QX versus QX a through Afrezza XXX% a is of in key of made as this the with Sciences as transition second. These XX%, has in you of more and some our highlight from weeks double double-digit XXXX. go because XXXX, XXXX. closed you TRx net deal the to XXX% gross into several gross has on continued we've show but detail Life were Technosphere on sequential important talk we million QX, impacted between million as XXXX. net to a in and about highlights. Therapeutics QX the seen that will top in let Now, well closed United
scientific months. and out with Afrezza over knowledge and our increase acumen as to several last continue several as study at there our by the conferences We presence major STAT the well
cohort of now and Additionally, progressing X are we underway our program, of well cohort X. pediatric completed
XX-year-old. Just old. trial to XX are pediatric where patients remind to of you, our dose cohort X the now, focused first we XX that on from is patients we're And part years to eight
to dramatically in position Deerfield $XX million non-dilutive financial collaboration balance. $X over $XX which of the has our million Our received, in paid October. by including with been We've in UT $XX with capital the reduced we down and been an October. closed debt million improved QX now, agreements, has we're million, And now that research
story into Therapeutics all not details. the Let those more and yet have for United who to of me go our detail followed new you are
So such the unique we outcomes lung. product patient focused for in we're areas treprostinil. to exclusive rights of the partnering a licensed with of be company very Well, on excited their collaboration worldwide in a
platform the agreement, PAH. of Technosphere have for this part to they exclusivity As
in As a we result as $XX gets expect low and October, of $XX payments, in approved $XX which we this, million royalties. million received upfront, expect in double-digit million we $XX milestone million we be the there'll expect of XXXX. And product and in XXXX,
at expect to have which partnered a of the drivers Therapeutics, and As well major shop, their we United the look product that couldn't in with upon, to continue experience is growth we're to that you glad patient and we better see continue is their do product improve to one continues company. Tyvaso, to
been if it'll but bring agreement $XX fees. our candidate research filter. Technosphere talked Additionally, provided compound and about development which there platform provides September. forward, bring that's million upfront, this $XX another this also licensing agreement us not was another back [Indiscernible] in disclosed, milestone to a in And million moves was forward, research
we four, non-lung that focus our compounds market. we the delivered Bucket are we So end over to remind of own financial use. products want day, have But and the on areas external molecules commitment I the for us. four lung, an one and we delivered today And those focus excited at forward molecules. that into acute forward look At just area get our two things they filing innovation find that of the of we area investments the bucket second interest. of these buckets patients. formulated And for on Bucket we of start will XX into and which time given known story are of these focus can of which new we to is to would known are bring but of compounds, resources, very Technosphere patients speed that our for three you the that's are with. already to
just important been takes let of But we the are saying on to I care over have standard Afrezza, we building switch mealtime time. me that awhile. insulin. changing Now next know in to it's habits Afrezza. focused know for
We insulin same and the we change expect don't used that have years XX overnight. for way to
changed in you the believability utilized lung And However, has need and as you when experience to here always about the being everything in using and quarter-on-quarter. but as other Afrezza, being is of That you had prescriber teach those here demonstrating and being we you talk discussion. XX I shift months insulin details are predominantly not to sit solve when to the it, the to messages, to to I are tone unique of the from need here And in go the safety dramatically Afrezza I but can pediatrics, think hey, disease our over you want who how base well down have end, pediatrics delivered and area as our doctors In take saying, being continues it, conversations confidence the for technology also future have go wanting of we an in believe last the we mealtime to I technology continued all see know. us to take the tell very you the it. of me in and open unmet have bring for won't marketing that's because a U.S. I
post next just show to starts about demonstrates you when really in than post for experience sugars after what eating, and your we the different sugars what's meal data meal, going a XX down. I about you going published it that think slide That is your is an X here up are hours. happen got see minutes really you going Afrezza. what are to September. think we This hour talking know And are very you until within don't
control to your you as the we are for as to see accelerated and X grow eating realtime in -- if an see base Lebre X really doctors as and on, that starts are curve that [ph] over And watching continue real-time And how about we be going testing the know to to them that give want Afrezza to and patients learn you want experience. feedback. will you patient penetrate we to feedback. sugars you It are what's here that who So use are thinks get real-time you we our market see hours that excited as your well and U.S. that patient time after and very
prescription. is here comment around Next our
data. So we there of look at two sets is
-- data. five see prescriber the have over in last the given come Terminals. see And based scripts little I XXX about on here of weekly that closed data internet. to to we and will prescriber weeks, on the broken for which detailed The is the we you Some is data public we XXX data have few is weeks week. talk have more a Bloomberg
But growth forward to We growth we digit XXX are last look up through now XXX. forward. QX numbers year. we what And we same almost XXX period QX year-to-date, breaking double to are and you go QX. the can see and as consistently to from breaking versus QX have We XX% had
years to to growing We further for see expect continue to come. it
treatment, which that is new was often our we around NRx. up show base have XXXX brand member, want to transparency get to business question to so and year-to-date Another base versus our versus I continue NBRx, data new continues and Rx up is XX% and to new business XX% is guys our XXXX grow this our you year-over-year that year-over-year.
momentum. continue to see we very So, positive
week, We should transitioned to about made We closing continue then that we a joining want in One, instrumental aware talent in see previously prescribers retain I prescribing in let deep be will QX, faster. every to QX our make And sales Marketing several we Officer, we you new it want know new all who helping diabetes increasing. Garrett, given to and changes us the of. great had new competitive background several head Chief be who marketers recruit Number who of job market. relationships, and hired with we and have starting us announced. two, you
our platform coming capital stabilized on and driving to a is said, management out That where company as holding track we our becoming the Steve. to term. she prospects, Three, Afrezza company plan transition functions be we priorities business by engine. rebalance will over our by are as include growth near future a spend Now company and these as Afrezza appropriate that it in years. back I to turn working program our to on growth we our to now And back tremendous our we openings we put and allocation over Technosphere on continue focus be growth development finally, driver major will the with the we office have balanced critical prudent believe to building
